Position in FTRE
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$7,146,458
-$1,457,952 QoQ
Shares Held
410,716
-64.0% QoQ
Ownership
0.432%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#38
of 334 holders
Holding Since
Sep 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Pacer Advisors, Inc. holds $626,935,191 across 141 Biotechnology names. FTRE ranks #9 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
369,451 | $230,367,476 | |
| 2 | INCY |
Incyte Corp
|
1,431,426 | $162,266,451 | |
| 3 | EXEL |
Exelixis, Inc.
|
1,096,682 | $59,670,467 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
72,465 | $35,995,539 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
146,264 | $35,245,236 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
506,545 | $28,984,504 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
228,060 | $17,850,256 | |
| 8 | HRMY |
Harmony Biosciences Holdings, Inc.
|
348,239 | $12,679,381 |
All Filings in FTRE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,146,458 | 410,716 | Shares | Sole | 2026-08-13 | |
| 2025-03-31 | $8,604,410 | 1,139,657 | Shares | Sole | 2025-05-06 | |
| 2024-12-31 | $112,899,751 | 6,053,606 | Shares | Sole | 2025-01-22 | |
| 2024-09-30 | $122,518,980 | 6,125,949 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $2,847 | 122 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $4,214 | 105 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $3,664 | 105 | Shares | Sole | 2024-01-16 | |
| 2023-09-30 | $3,745 | 131 | Shares | Sole | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||